Literature DB >> 24390132

Keratinocyte-specific mesotrypsin contributes to the desquamation process via kallikrein activation and LEKTI degradation.

Masashi Miyai1, Yuuko Matsumoto1, Haruyo Yamanishi1, Mami Yamamoto-Tanaka2, Ryoji Tsuboi3, Toshihiko Hibino4.   

Abstract

Kallikrein-related peptidases (KLKs) have critical roles in corneocyte desquamation and are regulated by lymphoepithelial Kazal-type inhibitor (LEKTI). However, it is unclear how these proteases are activated and how activated KLKs are released from LEKTI in the upper cornified layer. Recently, we reported cloning of a PRSS3 gene product, keratinocyte-specific mesotrypsin, from a cDNA library. We hypothesized that mesotrypsin is involved in the desquamation process, and the aim of the present study was to test this idea by examining the effects of mesotrypsin on representative desquamation-related enzymes pro-KLK5 and pro-KLK7. Incubation of mesotrypsin and these zymogens resulted in generation of the active forms. KLK activities were effectively inhibited by recombinant LEKTI domains D2, D2-5, D2-6, D2-7, D5, D6, D6-9, D7, D7-9, and D10-15, whereas mesotrypsin activity was not susceptible to these domains, and in fact degraded them. Immunoelectron microscopy demonstrated that mesotrypsin was localized in the cytoplasm of granular cells and intercellular spaces of the cornified layer. Proximity ligation assay showed close association between mesotrypsin and KLKs in the granular to cornified layers. Age-dependency analysis revealed that mesotrypsin was markedly downregulated in corneocyte extract from donors in their sixties, compared with younger donors. Collectively, our findings suggest that mesotrypsin contributes to the desquamation process by activating KLKs and degrading the intrinsic KLKs' inhibitor LEKTI.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24390132     DOI: 10.1038/jid.2014.3

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  37 in total

1.  Human mesotrypsin exhibits restricted S1' subsite specificity with a strong preference for small polar side chains.

Authors:  Edit Szepessy; Miklós Sahin-Tóth
Journal:  FEBS J       Date:  2006-06-05       Impact factor: 5.542

2.  Kallikrein-related peptidase 14 may be a major contributor to trypsin-like proteolytic activity in human stratum corneum.

Authors:  Kristina Stefansson; Maria Brattsand; Annelii Ny; Bo Glas; Torbjörn Egelrud
Journal:  Biol Chem       Date:  2006-06       Impact factor: 3.915

Review 3.  Prostate-specific antigen: an overlooked candidate for the targeted treatment and selective imaging of prostate cancer.

Authors:  Aaron M LeBeau; Maya Kostova; Charles S Craik; Samuel R Denmeade
Journal:  Biol Chem       Date:  2010-04       Impact factor: 3.915

4.  Evidence for a matriptase-prostasin proteolytic cascade regulating terminal epidermal differentiation.

Authors:  Sarah Netzel-Arnett; Brooke M Currie; Roman Szabo; Chen-Yong Lin; Li-Mei Chen; Karl X Chai; Toni M Antalis; Thomas H Bugge; Karin List
Journal:  J Biol Chem       Date:  2006-09-15       Impact factor: 5.157

5.  Identification and expression of the cDNA-encoding human mesotrypsin(ogen), an isoform of trypsin with inhibitor resistance.

Authors:  C N Nyaruhucha; M Kito; S I Fukuoka
Journal:  J Biol Chem       Date:  1997-04-18       Impact factor: 5.157

6.  A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation.

Authors:  Carla A Borgoño; Iacovos P Michael; Nahoko Komatsu; Arumugam Jayakumar; Ravi Kapadia; Gary L Clayman; Georgia Sotiropoulou; Eleftherios P Diamandis
Journal:  J Biol Chem       Date:  2006-12-11       Impact factor: 5.157

7.  Epidermal lamellar granules transport different cargoes as distinct aggregates.

Authors:  Akemi Ishida-Yamamoto; Michel Simon; Mari Kishibe; Yuki Miyauchi; Hidetoshi Takahashi; Shigetaka Yoshida; Timothy J O'Brien; Guy Serre; Hajime Iizuka
Journal:  J Invest Dermatol       Date:  2004-05       Impact factor: 8.551

Review 8.  Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer.

Authors:  Georgios Pampalakis; Georgia Sotiropoulou
Journal:  Biochim Biophys Acta       Date:  2007-06-14

Review 9.  LEKTI-1 in sickness and in health.

Authors:  T Roelandt; B Thys; C Heughebaert; A De Vroede; K De Paepe; D Roseeuw; B Rombaut; J-P Hachem
Journal:  Int J Cosmet Sci       Date:  2009-05-13       Impact factor: 2.970

10.  Matriptase initiates activation of epidermal pro-kallikrein and disease onset in a mouse model of Netherton syndrome.

Authors:  Katiuchia Uzzun Sales; Andrius Masedunskas; Alexandra L Bey; Amber L Rasmussen; Roberto Weigert; Karin List; Roman Szabo; Paul A Overbeek; Thomas H Bugge
Journal:  Nat Genet       Date:  2010-07-25       Impact factor: 38.330

View more
  12 in total

Review 1.  Kallikreins - The melting pot of activity and function.

Authors:  Magdalena Kalinska; Ulf Meyer-Hoffert; Tomasz Kantyka; Jan Potempa
Journal:  Biochimie       Date:  2015-09-25       Impact factor: 4.079

Review 2.  Putative functions of tissue kallikrein-related peptidases in vaginal fluid.

Authors:  Carla M J Muytjens; Stella K Vasiliou; Katerina Oikonomopoulou; Ioannis Prassas; Eleftherios P Diamandis
Journal:  Nat Rev Urol       Date:  2016-09-07       Impact factor: 14.432

3.  Mesotrypsin and caspase-14 participate in prosaposin processing: potential relevance to epidermal permeability barrier formation.

Authors:  Mami Yamamoto-Tanaka; Akira Motoyama; Masashi Miyai; Yukiko Matsunaga; Junko Matsuda; Ryoji Tsuboi; Toshihiko Hibino
Journal:  J Biol Chem       Date:  2014-05-28       Impact factor: 5.157

4.  Sequence and conformational specificity in substrate recognition: several human Kunitz protease inhibitor domains are specific substrates of mesotrypsin.

Authors:  Devon Pendlebury; Ruiying Wang; Rachel D Henin; Alexandra Hockla; Alexei S Soares; Benjamin J Madden; Marat D Kazanov; Evette S Radisky
Journal:  J Biol Chem       Date:  2014-10-09       Impact factor: 5.157

5.  KLK5 Inactivation Reverses Cutaneous Hallmarks of Netherton Syndrome.

Authors:  Laetitia Furio; Georgios Pampalakis; Iacovos P Michael; Andras Nagy; Georgia Sotiropoulou; Alain Hovnanian
Journal:  PLoS Genet       Date:  2015-09-21       Impact factor: 5.917

6.  KLK5 and KLK7 Ablation Fully Rescues Lethality of Netherton Syndrome-Like Phenotype.

Authors:  Petr Kasparek; Zuzana Ileninova; Olga Zbodakova; Ivan Kanchev; Oldrich Benada; Karel Chalupsky; Maria Brattsand; Inken M Beck; Radislav Sedlacek
Journal:  PLoS Genet       Date:  2017-01-17       Impact factor: 5.917

7.  Small molecule inhibitors of mesotrypsin from a structure-based docking screen.

Authors:  Olumide Kayode; Zunnan Huang; Alexei S Soares; Thomas R Caulfield; Zigang Dong; Ann M Bode; Evette S Radisky
Journal:  PLoS One       Date:  2017-05-02       Impact factor: 3.240

8.  PRSS3/Mesotrypsin and kallikrein-related peptidase 5 are associated with poor prognosis and contribute to tumor cell invasion and growth in lung adenocarcinoma.

Authors:  Honghai Ma; Alexandra Hockla; Christine Mehner; Matt Coban; Niv Papo; Derek C Radisky; Evette S Radisky
Journal:  Sci Rep       Date:  2019-02-12       Impact factor: 4.379

9.  Label-free stimulated Raman scattering microscopy visualizes changes in intracellular morphology during human epidermal keratinocyte differentiation.

Authors:  Mariko Egawa; Shinya Iwanaga; Junichi Hosoi; Makiko Goto; Haruyo Yamanishi; Masashi Miyai; Chika Katagiri; Kyoya Tokunaga; Takuya Asai; Yasuyuki Ozeki
Journal:  Sci Rep       Date:  2019-08-29       Impact factor: 4.379

10.  Multiple pathways are involved in DNA degradation during keratinocyte terminal differentiation.

Authors:  M Yamamoto-Tanaka; T Makino; A Motoyama; M Miyai; R Tsuboi; T Hibino
Journal:  Cell Death Dis       Date:  2014-04-17       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.